COMMUNIQUÉ DE PRESSE publié le 14/09/2023 à 14:30, il y a 1 année 2 mois Jaguar Health Shares Presentation Replay Link from September 11-13, 2023 H.C. Wainwright Annual Global Investment Conference
COMMUNIQUÉ DE PRESSE publié le 13/09/2023 à 14:30, il y a 1 année 2 mois Patent Issued in Japan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
COMMUNIQUÉ DE PRESSE publié le 12/09/2023 à 14:30, il y a 1 année 2 mois Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to National Institute of Allergy and Infectious Diseases for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
COMMUNIQUÉ DE PRESSE publié le 11/09/2023 à 14:30, il y a 1 année 2 mois Jaguar Health Shares Replay Link for September 7, 2023 Presentation at Emerging Growth Conference
COMMUNIQUÉ DE PRESSE publié le 07/09/2023 à 14:30, il y a 1 année 2 mois Jaguar Health's Executive VP Dr. Karen Brunke Joins BIO's Rare Disease and Orphan Drugs Committee
COMMUNIQUÉ DE PRESSE publié le 30/08/2023 à 14:30, il y a 1 année 2 mois The Science Times Publishes Article About Jaguar Health's Focus on Developing Crofelemer for Two Rare Disease Indications
COMMUNIQUÉ DE PRESSE publié le 28/08/2023 à 14:30, il y a 1 année 2 mois Jaguar Health to Present September 7 at Emerging Growth Conference and at the September 11-13 H.C. Wainwright Annual Global Investment Conference
COMMUNIQUÉ DE PRESSE publié le 24/08/2023 à 13:00, il y a 1 année 2 mois Jaguar Health Engages B2i Digital to Deploy Cutting-Edge Investor Engagement Campaign
COMMUNIQUÉ DE PRESSE publié le 17/08/2023 à 14:30, il y a 1 année 3 mois Napo Pharmaceuticals, a Jaguar Health Family Company, Reports Completion of Last Patient Last Visit for its Pivotal Phase 3 OnTarget Trial of Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea
COMMUNIQUÉ DE PRESSE publié le 16/08/2023 à 14:30, il y a 1 année 3 mois Napo Pharmaceuticals Surveys of Neurologists, Patients, and Caregivers Regarding Amyotrophic Lateral Sclerosis (ALS) Treatment Indicate Real World Burden of Diarrhea and Potential Treatment Interruption
Publié le 22/11/2024 à 16:15, il y a 6 heures 7 minutes NRJ GROUP - Le Conseil d'Etat rejette le recours de NRJ 12 et NRJ GROUP
Publié le 21/11/2024 à 06:58, il y a 1 jour 15 heures Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 22/11/2024 à 18:45, il y a 3 heures 37 minutes CORRECTING and REPLACING the Not-So-Secret Lives of REAL "Mormon" Wives - the Eye-Opening New Book From Cedar Fort Publishing & Media - is Now Available for Purchase, Just in Time for Christmas
Publié le 22/11/2024 à 16:00, il y a 6 heures 22 minutes Manimal Tales Unveils Two New Personalized Christmas-Themed Books to Spread Holiday Magic and Joy!
Publié le 22/11/2024 à 15:55, il y a 6 heures 27 minutes Independent Proxy Advisory Firm ISS Recommends Signal Gold Shareholders Vote for Arrangement Resolution and Private Placement Resolution
Publié le 22/11/2024 à 15:15, il y a 7 heures 7 minutes Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Publié le 22/11/2024 à 14:45, il y a 7 heures 37 minutes Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs
Publié le 22/11/2024 à 18:14, il y a 4 heures 8 minutes Fuller, Smith & Turner PLC: Transaction in own shares
Publié le 22/11/2024 à 17:53, il y a 4 heures 29 minutes Funding Circle Plc: POS-Transaction in Own Shares
Publié le 22/11/2024 à 16:55, il y a 5 heures 27 minutes EQS-Adhoc: Comment on withdrawn non-binding offer
Publié le 22/11/2024 à 16:00, il y a 6 heures 22 minutes Proposed cancellation of admission to trading
